Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2007

View Archived Issues

Crucell's West Nile vaccine meets phase I study endpoints

Nasalfent begins phase III program in breakthrough cancer pain

New phase I/II trial under way for TNFerade in head and neck cancer

IND acceptance for SPC/ENZ-2968 triggers milestone payment

Aranesp increases risk of death in cancer patients not receiving treatment

Novel inhibitor of protein-protein interactions in the Wnt pathway suppresses tumor growth in vivo

Oral entry inhibitor SP-10 shows antiviral activity in HCV

VRX-480773: a novel NNRTI with activity against efavirenz-resistant HIV

LAB International closes PharmaForm acquisition

Recent patents describe new agents for musculoskeletal and connective tissue disorders

Recent patents report novel therapeutic agents for HIV infection

New agents for schizophrenia and depression disclosed in recent patents

Targeting orexin receptors may be useful to treat sleep disorders

Yaz approved to treat acne in women

Promising phase II findings for INGN-225 in small cell lung cancer

GSK files prepandemic influenza vaccine in E.U.

Sunesis to advance phase II SCLC study of SNS-595 into second stage

Phase II trial explores topical AVR-118 as wound healing agent

RPI-78M begins phase IIb study in adrenomyeloneuropathy

Intravenous administration approved for Vidaza

Phase II enrollment open for glufosfamide in platinum-resistant ovarian cancer

Preliminary findings from phase IIb asthma study of IPL-512,602

DiabeCell cleared for Russian study in type 1 diabetes

Lexicon changes name, refocuses operations on drug discovery and development

Mirena approved in Japan

Pariet approved in Japan for H. pylori eradication

Relenza approved in Japan for influenza prophylaxis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...